Clinical Trial

Expansion Study of ALT001 in Patients With Multiple System Atrophy

Study acronym: ALT001 in MSA
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single-center, prospective, single-arm clinical study. The primary objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of ALT001 in the treatment of patients with multiple system atrophy (MSA) in a real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-12.
Trial Details
NCT Number NCT07476352
Lead Sponsor yilong Wang
Conditions Multiple System Atrophy
Enrollment 60 participants
Start Date 2026-05-06
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-30